Fortis Healthcare Limited share price

Key numbers

Market cap

₹ 63,254 Cr

Current price

₹ 837.85

52-week high / low

₹ 1,104 / 767

Stock P/E

60.2

Book value

₹ 131.1

Dividend yield

0.12%

ROCE

13.3%

ROE

11.1%

Debt to equity

0.35

Sales growth (3 yrs)

13.3%

Profit growth (3 yrs)

21.0%

1-year return

-12.8%

About Fortis Healthcare Limited

Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company services in the areas of cardiac science, nephrology, diabetology/endocrinology, foetal medicine, infectious diseases, mental health and behavioral science, oncology, orthopedics, physiotherapy and rehabilitation, rheumatology, urology, nuclear medicine, critical care, emergency and trauma, general surgery, internal medicine, neurointerventional radiology, obstetrics and gynaecology, pediatrics, pediatrics, vascular surgery, and support facilities. It also provides services in the areas of infertility medicine, dental science, endocrine surgery, geriatric medicine, liver transplant and hepatobiliary sciences, neurology, ophthalmology, pain and palliative medicine, pulmonology, thoracic surgery, gastroenterology sciences, dermatology, ENT, haematology, medical generics, neurology, organ transplant, radiology, and transfusion medicines. In addition, the company offers various spectrum integrated healthcare services ranging from clinics to quaternary care facilities and a range of ancillary services, as well as secondary, and tertiary care services. The company's healthcare verticals…

Quarterly results

Consolidated figures in ₹ crores

Concall summary (2026-09-10)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

• We have checked that thoroughly, and we are fairly confident that the outcome of this exercise should be in our favor.
• You know, the company is subject to incurring that legal expenses going forward also.

Growth & demand

• From an IHH perspective, given that at some point we were looking at Gleneagles and Fortis getting integrated, and you've also mentioned in case Fortis requires growth capital, you could look at in an infusion into Fortis.
• Fort is will be our growth engine to grow our India platform.

Margins & costs

• The second part of the foren sic audit is the examination of acquisition of controlling stake in FHL by IHH/NTK, including approvals, filing, etc , related to the such acquisition, and the subsequent utilization of investment amounts towards the acquisition of healthcare assets fr om RHT Health Trust in Singapore.
• I think we've done the right thing in terms of investment into the company, and Daiichi's act of trying to block us has been fairly unfair, and that's also costed us time from an MTO perspective.

Capex & expansion

• While we can address any questions you might have, I want to highlight upfront that the current order in no way changes, limits, or impedes any of our strategic or operational plans, including those related to our investment, capex, bed expansion, and our initiatives on the M&A front.
• Major M&A, etc, you have already heard from IHH, they are that they have no impediment in investing into the company.

Risks & challenges

• Firstly, over the last few years, Fort is has been on the receiving end of Daiichi Sankyo's legal challenges in India.
• So, again, cannot comment on what view the judge would take and since it's sub judice, but our view is we've been unfairly blocked over the years, and the MTO, which was delayed, was finally done only last year after almost seven years of waiting.

Peers in Medical Care Facilities

• Apollo Hospitals Enterprise Limited
• Max Healthcare Institute Limited
• Manipal Health Enterprises Limited
• Aster DM Quality Care Limited
• Global Health Limited
• Narayana Hrudayalaya Limited
• Krishna Institute of Medical Sciences Limited
• Rainbow Children's Medicare Limited
• Park Medi World Limited
• Yatharth Hospital & Trauma Care Services Limited